A population pharmacokinetic analysis shows that arylacetamide deacetylase (AADAC) gene polymorphism and HIV infection affect the exposure of rifapentine

Jose Francis, Simbarashe P. Zvada, Paolo Denti, Mark Hatherill, Salome Charalambous, Stanley Mungofa, Rodney Dawson, Susan Dorman, Nikhil Gupte, Lubbe Wiesner, Amina Jindani, Thomas S. Harrison, Adeniyi Olagunju, Deirdre Egan, Andrew Owen, Helen M. McIlleron

Research output: Contribution to journalArticle

Abstract

Rifapentine is a rifamycin used to treat tuberculosis. As is the case for rifampin, plasma exposures of rifapentine are associated with the treatment response. While concomitant food intake and HIV infection explain part of the pharmacokinetic variability associated with rifapentine, few studies have evaluated the contribution of genetic polymorphisms. We evaluated the effects of functionally significant polymorphisms of the genes encoding OATP1B1, the pregnane X receptor (PXR), constitutive androstane (CAR), and arylacetamide deacetylase (AADAC) on rifapentine exposure. Two studies evaluating novel regimens among southern African patients with drug-susceptible pulmonary tuberculosis were included in this analysis. In the RIFAQUIN study, rifapentine was administered in the continuation phase of antituberculosis treatment in 1,200-mg-once-weekly or 900-mg-twice-weekly doses. In the Daily RPE study, 450 or 600 mg was given daily during the intensive phase of treatment. Nonlinear mixed-effects modeling was used to describe the pharmacokinetics of rifapentine and to identify significant covariates. A total of 1,144 drug concentration measurements from 326 patients were included in the analysis. Pharma-cogenetic information was available for 162 patients. A one-compartment model with first-order elimination and transit compartment absorption described the data well. In a typical patient (body weight, 56 kg; fat-free mass, 45 kg), the values of clearance and volume of distribution were 1.33 liters/h and 25 liters, respectively. Patients carrying the AA variant (65.4%) of AADAC rs1803155 were found to have a 10.4% lower clearance. HIV-infected patients had a 21.9% lower bioavailability. Once-weekly doses of 1,200 mg were associated with a reduced clearance (13.2%) compared to that achieved with more frequently administered doses. Bioavailability was 23.3% lower among patients participating in the Daily RPE study than in those participating in the RIFAQUIN study. This is the first study to report the effect of AADAC rs1803155AA on rifapentine clearance. The observed increase in exposure is modest and unlikely to be of clinical relevance. The difference in bioavailability between the two studies is probably related to the differences in food intake concomitant with the dose. HIV-coinfected patients had lower rifapentine exposures.

Original languageEnglish (US)
Article numbere01964-18
JournalAntimicrobial agents and chemotherapy
DOIs
StatePublished - Apr 1 2019

Fingerprint

rifapentine
HIV Infections
Pharmacokinetics
Population
Genes
Biological Availability
Eating
HIV
Genetic Polymorphisms
Rifampin
Pulmonary Tuberculosis

Keywords

  • AADAC
  • Pharmacogenetics
  • Population pharmacokinetics
  • Rifapentine
  • SLCO1B1
  • Tuberculosis

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

A population pharmacokinetic analysis shows that arylacetamide deacetylase (AADAC) gene polymorphism and HIV infection affect the exposure of rifapentine. / Francis, Jose; Zvada, Simbarashe P.; Denti, Paolo; Hatherill, Mark; Charalambous, Salome; Mungofa, Stanley; Dawson, Rodney; Dorman, Susan; Gupte, Nikhil; Wiesner, Lubbe; Jindani, Amina; Harrison, Thomas S.; Olagunju, Adeniyi; Egan, Deirdre; Owen, Andrew; McIlleron, Helen M.

In: Antimicrobial agents and chemotherapy, 01.04.2019.

Research output: Contribution to journalArticle

Francis, J, Zvada, SP, Denti, P, Hatherill, M, Charalambous, S, Mungofa, S, Dawson, R, Dorman, S, Gupte, N, Wiesner, L, Jindani, A, Harrison, TS, Olagunju, A, Egan, D, Owen, A & McIlleron, HM 2019, 'A population pharmacokinetic analysis shows that arylacetamide deacetylase (AADAC) gene polymorphism and HIV infection affect the exposure of rifapentine', Antimicrobial agents and chemotherapy. https://doi.org/10.1128/AAC.01964-18
Francis, Jose ; Zvada, Simbarashe P. ; Denti, Paolo ; Hatherill, Mark ; Charalambous, Salome ; Mungofa, Stanley ; Dawson, Rodney ; Dorman, Susan ; Gupte, Nikhil ; Wiesner, Lubbe ; Jindani, Amina ; Harrison, Thomas S. ; Olagunju, Adeniyi ; Egan, Deirdre ; Owen, Andrew ; McIlleron, Helen M. / A population pharmacokinetic analysis shows that arylacetamide deacetylase (AADAC) gene polymorphism and HIV infection affect the exposure of rifapentine. In: Antimicrobial agents and chemotherapy. 2019.
@article{ff26fe8ce7b647a0ae59c13f2b9cb9b3,
title = "A population pharmacokinetic analysis shows that arylacetamide deacetylase (AADAC) gene polymorphism and HIV infection affect the exposure of rifapentine",
abstract = "Rifapentine is a rifamycin used to treat tuberculosis. As is the case for rifampin, plasma exposures of rifapentine are associated with the treatment response. While concomitant food intake and HIV infection explain part of the pharmacokinetic variability associated with rifapentine, few studies have evaluated the contribution of genetic polymorphisms. We evaluated the effects of functionally significant polymorphisms of the genes encoding OATP1B1, the pregnane X receptor (PXR), constitutive androstane (CAR), and arylacetamide deacetylase (AADAC) on rifapentine exposure. Two studies evaluating novel regimens among southern African patients with drug-susceptible pulmonary tuberculosis were included in this analysis. In the RIFAQUIN study, rifapentine was administered in the continuation phase of antituberculosis treatment in 1,200-mg-once-weekly or 900-mg-twice-weekly doses. In the Daily RPE study, 450 or 600 mg was given daily during the intensive phase of treatment. Nonlinear mixed-effects modeling was used to describe the pharmacokinetics of rifapentine and to identify significant covariates. A total of 1,144 drug concentration measurements from 326 patients were included in the analysis. Pharma-cogenetic information was available for 162 patients. A one-compartment model with first-order elimination and transit compartment absorption described the data well. In a typical patient (body weight, 56 kg; fat-free mass, 45 kg), the values of clearance and volume of distribution were 1.33 liters/h and 25 liters, respectively. Patients carrying the AA variant (65.4{\%}) of AADAC rs1803155 were found to have a 10.4{\%} lower clearance. HIV-infected patients had a 21.9{\%} lower bioavailability. Once-weekly doses of 1,200 mg were associated with a reduced clearance (13.2{\%}) compared to that achieved with more frequently administered doses. Bioavailability was 23.3{\%} lower among patients participating in the Daily RPE study than in those participating in the RIFAQUIN study. This is the first study to report the effect of AADAC rs1803155AA on rifapentine clearance. The observed increase in exposure is modest and unlikely to be of clinical relevance. The difference in bioavailability between the two studies is probably related to the differences in food intake concomitant with the dose. HIV-coinfected patients had lower rifapentine exposures.",
keywords = "AADAC, Pharmacogenetics, Population pharmacokinetics, Rifapentine, SLCO1B1, Tuberculosis",
author = "Jose Francis and Zvada, {Simbarashe P.} and Paolo Denti and Mark Hatherill and Salome Charalambous and Stanley Mungofa and Rodney Dawson and Susan Dorman and Nikhil Gupte and Lubbe Wiesner and Amina Jindani and Harrison, {Thomas S.} and Adeniyi Olagunju and Deirdre Egan and Andrew Owen and McIlleron, {Helen M.}",
year = "2019",
month = "4",
day = "1",
doi = "10.1128/AAC.01964-18",
language = "English (US)",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",

}

TY - JOUR

T1 - A population pharmacokinetic analysis shows that arylacetamide deacetylase (AADAC) gene polymorphism and HIV infection affect the exposure of rifapentine

AU - Francis, Jose

AU - Zvada, Simbarashe P.

AU - Denti, Paolo

AU - Hatherill, Mark

AU - Charalambous, Salome

AU - Mungofa, Stanley

AU - Dawson, Rodney

AU - Dorman, Susan

AU - Gupte, Nikhil

AU - Wiesner, Lubbe

AU - Jindani, Amina

AU - Harrison, Thomas S.

AU - Olagunju, Adeniyi

AU - Egan, Deirdre

AU - Owen, Andrew

AU - McIlleron, Helen M.

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Rifapentine is a rifamycin used to treat tuberculosis. As is the case for rifampin, plasma exposures of rifapentine are associated with the treatment response. While concomitant food intake and HIV infection explain part of the pharmacokinetic variability associated with rifapentine, few studies have evaluated the contribution of genetic polymorphisms. We evaluated the effects of functionally significant polymorphisms of the genes encoding OATP1B1, the pregnane X receptor (PXR), constitutive androstane (CAR), and arylacetamide deacetylase (AADAC) on rifapentine exposure. Two studies evaluating novel regimens among southern African patients with drug-susceptible pulmonary tuberculosis were included in this analysis. In the RIFAQUIN study, rifapentine was administered in the continuation phase of antituberculosis treatment in 1,200-mg-once-weekly or 900-mg-twice-weekly doses. In the Daily RPE study, 450 or 600 mg was given daily during the intensive phase of treatment. Nonlinear mixed-effects modeling was used to describe the pharmacokinetics of rifapentine and to identify significant covariates. A total of 1,144 drug concentration measurements from 326 patients were included in the analysis. Pharma-cogenetic information was available for 162 patients. A one-compartment model with first-order elimination and transit compartment absorption described the data well. In a typical patient (body weight, 56 kg; fat-free mass, 45 kg), the values of clearance and volume of distribution were 1.33 liters/h and 25 liters, respectively. Patients carrying the AA variant (65.4%) of AADAC rs1803155 were found to have a 10.4% lower clearance. HIV-infected patients had a 21.9% lower bioavailability. Once-weekly doses of 1,200 mg were associated with a reduced clearance (13.2%) compared to that achieved with more frequently administered doses. Bioavailability was 23.3% lower among patients participating in the Daily RPE study than in those participating in the RIFAQUIN study. This is the first study to report the effect of AADAC rs1803155AA on rifapentine clearance. The observed increase in exposure is modest and unlikely to be of clinical relevance. The difference in bioavailability between the two studies is probably related to the differences in food intake concomitant with the dose. HIV-coinfected patients had lower rifapentine exposures.

AB - Rifapentine is a rifamycin used to treat tuberculosis. As is the case for rifampin, plasma exposures of rifapentine are associated with the treatment response. While concomitant food intake and HIV infection explain part of the pharmacokinetic variability associated with rifapentine, few studies have evaluated the contribution of genetic polymorphisms. We evaluated the effects of functionally significant polymorphisms of the genes encoding OATP1B1, the pregnane X receptor (PXR), constitutive androstane (CAR), and arylacetamide deacetylase (AADAC) on rifapentine exposure. Two studies evaluating novel regimens among southern African patients with drug-susceptible pulmonary tuberculosis were included in this analysis. In the RIFAQUIN study, rifapentine was administered in the continuation phase of antituberculosis treatment in 1,200-mg-once-weekly or 900-mg-twice-weekly doses. In the Daily RPE study, 450 or 600 mg was given daily during the intensive phase of treatment. Nonlinear mixed-effects modeling was used to describe the pharmacokinetics of rifapentine and to identify significant covariates. A total of 1,144 drug concentration measurements from 326 patients were included in the analysis. Pharma-cogenetic information was available for 162 patients. A one-compartment model with first-order elimination and transit compartment absorption described the data well. In a typical patient (body weight, 56 kg; fat-free mass, 45 kg), the values of clearance and volume of distribution were 1.33 liters/h and 25 liters, respectively. Patients carrying the AA variant (65.4%) of AADAC rs1803155 were found to have a 10.4% lower clearance. HIV-infected patients had a 21.9% lower bioavailability. Once-weekly doses of 1,200 mg were associated with a reduced clearance (13.2%) compared to that achieved with more frequently administered doses. Bioavailability was 23.3% lower among patients participating in the Daily RPE study than in those participating in the RIFAQUIN study. This is the first study to report the effect of AADAC rs1803155AA on rifapentine clearance. The observed increase in exposure is modest and unlikely to be of clinical relevance. The difference in bioavailability between the two studies is probably related to the differences in food intake concomitant with the dose. HIV-coinfected patients had lower rifapentine exposures.

KW - AADAC

KW - Pharmacogenetics

KW - Population pharmacokinetics

KW - Rifapentine

KW - SLCO1B1

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=85063677013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063677013&partnerID=8YFLogxK

U2 - 10.1128/AAC.01964-18

DO - 10.1128/AAC.01964-18

M3 - Article

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

M1 - e01964-18

ER -